Sequist et al. (2020) [150] evaluated the combination of osimertinib and savolitinib (a small-molecule MET tyrosine kinase inhibitor) in patients with EGFR-mutant NSCLC and MET amplification. This evidence concerns the gene MET and non-small cell lung carcinoma.